Q32 Bio (NASDAQ:QTTB – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
Profitability
This table compares Q32 Bio and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Q32 Bio | N/A | -146.18% | -54.49% |
| ARS Pharmaceuticals | N/A | -22.56% | -21.82% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Q32 Bio and ARS Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Q32 Bio | 0 | 4 | 4 | 0 | 2.50 |
| ARS Pharmaceuticals | 0 | 0 | 4 | 2 | 3.33 |
Valuation and Earnings
This table compares Q32 Bio and ARS Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Q32 Bio | -$6.65 million | -6.57 | -$112.96 million | ($14.25) | -0.25 |
| ARS Pharmaceuticals | $2.57 million | 423.10 | -$54.37 million | ($0.51) | -21.92 |
ARS Pharmaceuticals has higher revenue and earnings than Q32 Bio. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Q32 Bio has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Institutional and Insider Ownership
31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by company insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
ARS Pharmaceuticals beats Q32 Bio on 11 of the 13 factors compared between the two stocks.
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.
